2023 in review: FDA approvals of new medicines.
Drug Discov Today
; 29(5): 103966, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38552777
ABSTRACT
An analysis of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval of 69 new entities in the year 2023, 50 % more than in the previous year. Oncology drugs tied with congenital and infectious diseases drugs for the most approvals. Although orphan and priority approvals continued at a high pace, the rate of fast-track approvals continued to decline. The rate of industry consolidation also picked up again after decreasing slightly in 2022.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
United States Food and Drug Administration
/
Drug Approval
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Drug Discov Today
/
Drug discov. today
/
Drug discovery today
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2024
Document type:
Article
Country of publication:
United kingdom